Navigation Links
NIH News Confirms Trend in Stem Cell 'Storage' Facilities, says CEO of San Diego-based Bio-Matrix Scientific Group

SAN DIEGO, March 26 /PRNewswire-FirstCall/ -- David Koos, Chairman and CEO of San Diego-based Bio-Matrix Scientific Group, Inc. (OTC Bulletin Board: BMSN) announced today that the important discovery reported on Wednesday, March 25 by researchers at the National Institutes of Health (NIH;, which has implications for Leukemia treatment and artificially culturing blood cells, validates a new direction for stem cell "storage" facilities that meet rigid state and federal regulatory requirements. The researchers deciphered a key sequence of events governing whether the stem cells that produce red and white blood cells remain anchored to the bone marrow, or migrate into the circulatory system - an important discovery that will advance understanding of how blood cells and immune cells are generated.

"The findings of NIH researchers have implications for culturing infection-fighting immune cells outside the body, where they could be temporarily held in storage during chemotherapy and other treatments which suppress the immune system. This discovery confirms a new trend for commercial stem cell storage facilities for research and treatment of diseases, and their important role in public and private stem cell research efforts now and into the future," said Koos.

BMSN, an emerging research and development biotechnology company, opened its commercial cryogenic stem cell storage and processing facility in 2008 focusing on stem cells derived from cord blood and peripheral blood. BMSN's 15,000 sq. ft. cryogenic stem cell banking facility is highly secured and technologically advanced and is now fully operational.

"There are about 30 private cord blood storage facilities in the U.S. and more than 150 of these facilities located worldwide," stated Koos.

About Bio-Matrix Scientific Group

Bio-Matrix Scientific Group Inc. (OTCBB: BMSN) is a biotech research and development company headquartered in San Diego, Ca. with a 15,000 square foot facility that houses two secure cryogenic stem cell banks, three research laboratories, aseptic cellular/tissue class 10,000/100 processing lab, hematology, microbiology and flow cytometry laboratories. The company also commercializes medical devices and monitoring systems for the growing worldwide stem cell research market.


This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.

SOURCE Bio-Matrix Scientific Group Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Barr Confirms Filing an Application With a Paragraph IV Certification for Femcon(R) FE Chewable Oral Contraceptive Product
2. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
3. Recent Study Confirms Alimentary Healths Bifantis(R) Demonstrates Efficacy in the Treatment of Irritable Bowel Syndrome
4. Barr Confirms Patent Challenge of Focalin(R) XR
5. Barr Confirms Patent Challenge of Eloxatin(R) Injectable, 5mg/mL
6. Barr Confirms Patent Challenge of Namenda(R) Tablets, 5mg & 10mg
7. Icahn Confirms Intention to Nominate Three Directors at Biogen
8. Barr Confirms Patent Challenge of Avodart(R) Soft Gelatin Capsules, 0.5mg
9. PPD Confirms Takedas NDA Filing of Alogliptin with U.S. Food and Drug Administration
10. Publication in Clinical Cancer Research Confirms Ability of Peregrines Bavituximab to Target Tumor Blood Vessels with Excellent Specificity
11. Research Confirms Better Oil from New DuPont High Oleic Soybean Trait
Post Your Comments:
(Date:6/23/2016)... , ... June 23, 2016 , ... ... YM (Yeast and Mold) microbial test has received AOAC Research Institute approval 061601. ... microbial tests introduced last year,” stated Bob Salter, Vice President of Regulatory and ...
(Date:6/23/2016)... ... June 23, 2016 , ... STACS DNA Inc., the ... at the Arkansas State Crime Laboratory, has joined STACS DNA as a Field Application ... team,” said Jocelyn Tremblay, President and COO of STACS DNA. β€œIn further expanding our ...
(Date:6/23/2016)... On Wednesday, June 22, 2016, the ... the Dow Jones Industrial Average edged 0.27% lower to finish ... 0.17%. has initiated coverage on the following equities: Infinity ... NKTR ), Aralez Pharmaceuticals Inc. (NASDAQ: ... ). Learn more about these stocks by accessing their free ...
(Date:6/23/2016)... June 23, 2016 ... report to its pharmaceuticals section with historic and ... and much more. Complete report on ... pages, profiling 15 companies and supported with 261 ... . The Global Cell ...
Breaking Biology Technology:
(Date:6/2/2016)... 2, 2016   The Weather Company , an IBM ... an industry-first capability in which consumers will be able to ... ask questions via voice or text and receive relevant information ... Marketers have long sought an advertising solution that ... be personal, relevant and valuable; and can scale across millions ...
(Date:5/16/2016)... --  EyeLock LLC , a market leader of iris-based ... IoT Center of Excellence in Austin, Texas ... embedded iris biometric applications. EyeLock,s iris authentication ... with unmatched biometric accuracy, making it the most proven ... platform uses video technology to deliver a fast and ...
(Date:4/28/2016)... , April 28, 2016 First quarter ... (139.9), up 966% compared with the first quarter of 2015 ... totaled SEK 589.1 M (loss: 18.8) and the operating margin was ... (loss: 0.32) Cash flow from operations was SEK 249.9 ... 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. The ...
Breaking Biology News(10 mins):